| Literature DB >> 31109332 |
Wei Tang1,2, Hongbo Gao1,2, Dalong Ni3, QiFeng Wang2,4, Bingxin Gu2,5,6, Xinhong He7,8, Weijun Peng9,10.
Abstract
BACKGROUND: Nanotechnology in medicine has greatly expanded the therapeutic strategy that may be explored for cancer treatment by exploiting the specific tumor microenvironment such as mild acidity, high glutathione (GSH) concentration and overproduced hydrogen peroxide (H2O2). Among them, tumor microenvironment responsive chemodynamic therapy (CDT) utilized the Fenton or Fenton-like reaction to produce excess hydroxyl radical (·OH) for the destruction of tumor cells. However, the produced ·OH is easily depleted by the excess GSH in tumors, which would undoubtedly impair the CDT's efficiency. To overcome this obstacle and enhance the treatment efficiency, we design the nanoplatforms for magnetic resonance imaging (MRI)-guided CDT.Entities:
Keywords: BSA-templated; Chemodynamic therapy; GSH; MRI
Mesh:
Substances:
Year: 2019 PMID: 31109332 PMCID: PMC6528315 DOI: 10.1186/s12951-019-0501-3
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Schematic illustration of CuS:Gd NPs for MRI-guided CDT, the nanoparticles could simultaneously react with GSH and H2O2 to enhance the generation of ·OH for tumor CDT
Fig. 2Characterization of CuS:Gd NPs. a TEM images of CuS:Gd NPs. b The longitudinal relaxation rate of the CuS:Gd NPs, Inset: Corresponding MR images. c The degradation performance of CuS:Gd NPs on MB at different time points (1 min, 3 min, 5 min, 10 min, 20 min, 30 min, 60, min, 90 min, 120 min and 240 min) (n = 3, mean ± SD). d The degradation of MB under different pH values (5.4, 6.5 and 7.4), indicating the negligible difference under different pH conditions. e EPR spectra of different groups (CuS:Gd-G only, CuS:Gd-G with H2O2 at pH 7.4, CuS:Gd-G with H2O2 at pH 6.5 and CuS:Gd-G with H2O2 at pH 5.4) with the 5,5-dimethyl-l-pyrroline N-oxide (DMPO) as the spin trap to detect the ·OH generation during the reaction
Fig. 3In vitro toxicity on normal cells and CDT performance on cancer cells of CuS:Gd NPs. a Cell viability of CuS:Gd NPs with different concentrations on the normal cells (LO2 cell) at 24 h and 48 h after co-incubation, demonstrating the well biocompatibility of CuS:Gd NPs. (n= 6, mean ± SD). b Cell viability of CuS:Gd NPs with different concentrations on the cancer cells (4T1 cell) at 24 h and 48 h after co-incubation (n= 6, mean ± SD). c Cell viability of CuS:Gd NPs with different concentrations on the normal cells (LO2 cells) at 72 h after co-incubation. (n= 6, mean ± SD). d Confocal images of DCFH-DA (2′,7′-dichlorofluorescein diacetate) stained 4T1 cells of two groups (control group and the CuS:Gd NPs group) at different times points. Scale bar: 50 μm. e Confocal images of the live and dead cells stained with calcein/PI of different groups (saline group and the CuS:Gd NPs group co-cultured with 4T1 cells for 24 h), demonstrating the well CDT capability of CuS:Gd NPs. Scale bar: 100 μm
Fig. 4In vivo MRI performance and CDT ability of CuS:Gd NPs. a T-weighted MR images of mice at different time points after the injection of CuS:Gd NPs (25 mg/kg) and the commercial Magnevist (Gd-DTPA) for comparison, confirming the well MRI behavior of CuS:Gd NPs in vivo. b Time course change of the tumors volume of different groups (saline group and CuS:Gd NPs group), indicating the excellent CDT performance of CuS:Gd NPs in vivo. (n= 6, mean ± SD). c Body weights change of the 4T1 tumor-bearing Balb/c mice during CDT process. (n= 6, mean ± SD). d H&E staining of the tumor tissues from the 4T1 tumor-bearing Balb/c mice from different groups. Scale bar: 50 μm. e H&E staining of the main organs after the treatment of CuS:Gd NPs